Press Releases

Date Title and Summary  
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for first quarter
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California --(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017 .
Toggle Summary Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals,
Toggle Summary Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
— Florida Plant Can Produce AR101 for Peanut Allergy for Global Market — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today hosted a ribbon-cutting ceremony to
Toggle Summary Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 5, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— “Real-World” Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif. --(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007)
Toggle Summary Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Unique Dataset of Double-Blind, Placebo-Controlled Food Challenges from Phase 3 PALISADE North American Screened Population Is Largest Ever Collected on Peanut-Allergic Patients and Provides Valuable Insights for Future Study — — 95% Adherence to Daily At-Home AR101 Dosing in Blinded Phase 2
Toggle Summary Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BRISBANE, Calif. & HELSINKI--(BUSINESS WIRE)--Jun. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European